News
Pharma update | Apixaban patent and SPC provisionally held invalid
In its decision of 10 May 2022 in PI proceedings between Bristol-Myers Squibb Holdings Ireland Unlimited Company (“BMS”) and Sandoz B.V. (“Sandoz”), the PI judge of the District Court of The Hague denied BMS’ claim for injunctive relief regarding the sale of generic apixaban by Sandoz. According to the Judge, there is no inventive step
Read more ›
Court finds Mammoet’s press release unlawful
Huisman had issues a press announcement that it had concluded an agreement with BMW for the design and construction of a so-called “ringer crane”, a special kind of heavy-lifting land cranes. Following Huisman’s press statement, Mammoet issued a press release entitled “Mammoet starts investigation of patent infringement by Huisman and BMS”, in which it refers
Read more ›
BarentsKrans repels Novartis’ bid for fingolimod PI
The District Court of The Hague (Provisions Judge) has rejected Novartis’ application, based on a patent application, for a preliminary injunction (PI), meaning Mylan can market its generic drug containing fingolimod in the Netherlands at least prior to the grant of the patent. The EPO’s Technical Board of Appeal had recently cleared the way for
Read more ›
Legal 500 EMEA 2022: “Partner involvement, all areas in-house, professional juniors”
This week the Legal 500 published its’ 2022 edition. We are honoured to again have received excellent rankings this year. BarentsKrans has been ranked as Top Tier Firm in Employment Law and has been recommended in no less than ten practice areas. A special mention goes to Joost Fanoy who was listed as Leading Individual
Read more ›
Pharma update | Market entry of generic fingolimod before patent grant is not unlawful
In its interim decision of 22 March 2022 the PI judge of the District Court of The Hague ruled in the PI proceedings in Novartis v Mylan that the market entry by Mylan with its generic fingolimod 0.5mg product prior to Novartis’ patent entering into force, is not unlawful. Given the very short time between
Read more ›
Chambers Europe 2022: “accessible, specialist and pragmatic”
After receiving honourable mentions in the Chambers Global Guide 2022 last month, we are proud and grateful to have been ranked in the Chambers Europe Guide 2022. Chambers Europe ranks the leading lawyers and law firms across Europe and is one of the leading guidebooks within the international field of advocacy. The annual rankings are
Read more ›
Jaap Bremer ranked in WTR 1000
The World Trademark Review has recommended Jaap Bremer in the WTR 1000, a guide that identifies the top trademark professionals in key jurisdictions around the globe. “Hands-on, approachable and knowledgeable”, Bremer is “an effective lawyer who not only considers the legal aspects of a case but the client’s commercial interests too”. “His profound and strategic
Read more ›
Telecoms update | Court orders submission of third party license and settlement agreements in FRAND case and imposes confidentiality regime; AASI granted ex parte
Recently, two interesting judgments were published in separate SEP/FRAND proceedings. The first decision pertains to a confidentiality regime and the second to an ex parte AASI. Confidentiality regime In the SEP/FRAND proceedings between Philips et al. vs. Xiaomi et al the District Court of The Hague (“DC”) decided on 14 July 2021 (decision published in
Read more ›
Chambers Global 2022 rankings: excellent results for BarentsKrans
We are excited to share the newest rankings of the Chambers Global Guide 2022. BarentsKrans once again received several honourable mentions for Corporate/ M&A, Dispute Resolution and Intellectual Property. Mentions Chambers Global 2022 The Chambers Global Guide ranks the top lawyers and law firms in over 200 jurisdictions across the world. The annual rankings are based
Read more ›
Pharma update | Court of Appeal overturns ruling District Court in Astrazeneca v Menzis
In an earlier Pharma Update, we reported on the judgment of the District Court of The Hague of 14 October 2020 in which AstraZeneca AB (“AstraZeneca”) was ordered to pay damages to health insurer Menzis Zorgverzekeraar NV (“Menzis”) for having enforced a patent that was later invalidated against a generic company. This judgment has now
Read more ›
